

Publications / Poster Presentations

1. Relationship Between Glycemic Control and Differences Between Parental and Child Measures of Diabetes Related Stress in Children with Type 1 Diabetes. Brenner DJ, Rajiyah T, Chummar J, Abugroun I, Oppenheimer E, Mamkin I. Poster Presentation, 10th International Meeting of Pediatric Endocrinology, September 14-17, 2017, Washington, DC
2. Central Precocious Puberty Associated with a Dax-1 (NROB1) Mutation Causing Adrenal Hypoplasia Congenita. Brenner D, Elbashir A. Poster Presentation, Endocrine Society Annual Meeting, May 5-8, 2015, San Diego, CA
3. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial. [Backeljauw PF](#), [Miller BS](#), [Dutailly P](#), [Houchard A](#), [Lawson E](#), [Hale DE](#), [Reiner B](#), [Sperling MA](#); [MS316 Study Group](#). [Horm Res Paediatr](#). 2015;83(4):268-79. doi: 10.1159/000371799. Epub 2015 Mar 6.
4. A four-year, open-label, multi-center, randomized, two-arm study of Genotropin® in patients with idiopathic short stature: comparison of an individualized, target-driven treatment regimen to standard dosing of Genotropin® - analysis of two-year data. [Counts DR](#), [Silverman LA](#), [Geffner ME](#), [Rajcic N](#), [Hey-Hadavi J](#), [Thornton PS](#), [Wajnrajch MP](#); [ISS Study Group](#). [Horm Res Paediatr](#). 2013;80(4):242-51. doi: 10.1159/000354126. Epub 2013 Sep 10.
5. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. [Sherry N](#), [Hagopian W](#), [Ludvigsson J](#), [Jain SM](#), [Wahlen J](#), [Ferry RJ Jr](#), [Bode B](#), [Aronoff S](#), [Holland C](#), [Carlin D](#), [King KL](#), [Wilder RL](#), [Pillemer S](#), [Bonvini E](#), [Johnson S](#), [Stein KE](#), [Koenig S](#), [Herold KC](#), [Daifotis AG](#); [Protégé Trial Investigators](#). [Lancet](#). 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.
6. Optimal Hyperlipidemia Monitoring in Children and Adolescents with Type 1 Diabetes Mellitus. Allen HA, Brenner D, Reiter O. Poster Presentation, Lawson Wilkins Pediatric Endocrine Society Meeting, Honolulu, Hawaii, May 2008
7. Prospective Detection Of Hyperglycemia In Critically Ill Children Using Continuous Glucose Monitoring. Allen HF, Rake A, Roy M, Brenner D, McKiernan CA. [Pediatric Critical Care Medicine](#). 9(2):153-158, March 2008.
8. Association Between Phone Contact And Inter-visit Glycemic Control In Type 1 Diabetic Children. Brenner D, Ben-Chaim A, Allen HF, Reiter EO. Presented at American Diabetes Association Scientific Session, Chicago, IL, June 22-24, 2007.
9. Does Increased BMI Impair Predicted Adult Height in Female Patients Treated with Depot GnRH for Precocious Puberty? Morneault E, Allen HA, Brenner D, Poster presentation, Lawson Wilkins Pediatric Endocrine Society Meeting, Toronto, Canada, May 7, 2007.

10. Birth Weight Percentiles in Obese Hyperinsulinemic and Obese Hyperandrogenemic Adolescent Females Compared to Obese Controls. Brenner D, Allen HF, Reiter EO. Poster presentation, Endocrine Society Annual Meeting, Boston, MA, June 2006.
11. Assessment of Body Composition in Girls treated for Precocious Puberty with GnRH Agonists. Brenner D, Allen HF, Reiter EO. Poster presentation, ESPE-LWPES joint meeting, Lyon, France, September 2005.
12. A randomized controlled trial of OCP vs OCP with metformin in adolescents with PCOS. Allen HF, Brenner D, Reiter, EO. Poster presentation, ESPE-LWPES joint meeting, Lyon, France, September 2005.
13. Parental Attitudes about Hypoglycemia in Type I Diabetics. Brenner D, Carey DE, Frank GR, Kreitzer P. Poster presentation, Endocrine Society Annual Meeting, San Diego, CA, June 2005.
14. Acquired Abnormalities Of The Hypothalamic-Pituitary Axis Leading To Growth Impairment. Brenner DJ, Reiter EO. Chapter, in "Clinical Pediatric Endocrinology" 5th Edition, Blackwell Publishing, 2005 Edited by Charles Brook.
15. Immunoregulatory T Cell Population In New-onset Type I Diabetic Children Compared To That Of Normal Children. Brenner DJ, McCloskey TW, Pahwa S, Speiser PW Poster presentation, Endocrine Society Annual Meeting, New Orleans, LA, June 2004.
16. Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency. Speiser PW, Brenner DJ. *Endocrinologist*. 13(4):334-340, July/August 2003.
17. Successful Computerization of a Hospital-Based Pediatric Endocrinology Practice. Brenner DJ, Carey DE, Frank GR, Fort P, Kreitzer PK, Speiser PW Poster presentation, Lawson Wilkins Pediatric Endocrine Society Meeting, Baltimore, MD, May 2002.
18. Precocious Puberty in Rubinstein-Taybi Syndrome. Brenner DJ, Speiser PW. Poster presentation, Endocrine Society Annual Meeting, Denver, CO, June, 2001.
19. Profiles of obese children presenting for metabolic evaluation. Anavian J, Brenner DJ, Fort P, Speiser PW. *Journal of Pediatric Endocrinology and Metabolism* 2001 Sep Oct;14(8):1145-50

Research

- Improving Glycemic Control in Children and Adolescents with Type 1 Diabetes Mellitus by Screening for and Providing Treatment for Diabetes-Related Depression, 2016 – present
- Principal investigator, Macrogenics Protégé, Protégé Extension, Protégé Subcutaneous, and Protégé Encore studies, 2008 - 2012
- Principal investigator, Pfizer "Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature", 2008 - 2012
- Principal investigator , Insmed, "Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome", 2006
- Principal investigator, Tercica, IGF-1 and growth hormone combined treatment study, 2008 - 2012
- Principal investigator, Tercica, "Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) treatment of pre-pubertal children with growth failure associated with primary IGF-1 Deficiency, An Open Label Multi Center, Extension Study", 2008 - 2012
- Principal Investigator, A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric

- Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone; Bristol- Myers Squibb, 2012 - 2013
- Principal Investigator, Colesevelam oral suspension as monotherapy or add-on to metformin therapy in pediatric subjects with type 2 diabetes mellitus; Daiichi Sankyo Pharma Solutions, 2012 - 2015
 - Principal Investigator, An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty; Debio Pharm Group, 2012 - 2014
 - Principal Investigator, Natural history study of the development of type 1 diabetes; Trial Net , 2012 – present
 - Sub investigator, Novo-Nordisk, “Norditropin National Registry protocol”, 2010 - present
 - Sub investigator, Pfizer, “KIGS Registry for Growth Hormone Therapy”, 2010 - 2012
 - Sub investigator, Eli Lilly, “GENESIS” registry , 2012 - 2015
 - Sub investigator, Genentech “A Postmarketing Surveillance Program for Nutropin, Nutropin AQ, and Protropin”, 2010
 - Principal Investigator, Versartis, VRS-317 (long-acting hGH) in Children with Growth Hormone Deficiency, 2013

Principal Investigator, Novo Nordisk, Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes, 2012 - 2015